Objective-Considerable evidence supports the early involvement of monocyte/macrophage recruitment to activated endothelial cells by leukocyte adhesion molecules during atherogenesis. AMP-activated protein kinase (AMPK) is highly expressed in vascular endothelial cells, but its impact on monocyte adhesion and the related mechanisms are not fully understood. The present study was designed to evaluate the impact of and gain mechanistic insight into the signaling coupling AMPK function to the antiinflammatory response.
and histone acetyltransferases (HATs). 6 HATs increase histone acetylation, thereby reducing DNA-histone binding and facilitating gene transcription, whereas HDACs act in the opposite way. 7 Among the HAT family members, the transcriptional coactivator p300 is a critical component of the transcriptional machinery that modifies chromatin organization and participates in the regulation of gene transcription. 8, 9 The orchestration of these activities by p300 involves an enzymatic activity through a HAT domain for histone H3 and H4 acetylation and several other substrates, including transcriptional regulators, resulting in enhanced gene transcription along diverse biological pathways, including inflammation. 10 -13 Because p300 activity is regulated via phosphorylation, it is believed that p300 HAT activity is a central integrator of various signaling pathways in the nucleus. 14 -16 Thus, epigenetic histone acetylation modifiers have become new targets for therapy in cardiovascular disease.
AMP-activated protein kinase (AMPK) is a member of a metabolite-sensing protein kinase family, contains a catalytic ␣ subunit and regulatory ␤ and ␥ subunits, and functions as a protein serine/threonine kinase. 17 The activation of AMPK attenuates anabolic processes, such as the synthesis of proteins, fatty acids, and cholesterol, but stimulates ATPgenerating catabolic pathways. 18 Recent findings, including our own, have demonstrated that AMPK is also present in the endothelium and maintains endothelial homeostasis in response to a number of stimuli (including proinflammatory cytokines and oxidative damage). 19 -21 However, the impact of AMPK on EC activation and the underlying epigenetic mechanism remains unknown. There are several reports linking AMPK activation with alterations in gene expression via the phosphorylation and modulation of histone acetylases. 22, 23 Given the importance of histone acetylases in regulating the endothelial proinflammatory response, the possible link between AMPK activity and acetylation/deacetylation is warranted. In this study, we evaluated the effect of AMPK on histone acetylases activity and its impact on endothelial activation in cultured human ECs. First, we found that pharmacological and genetic activation of AMPK in cultured human ECs led to the attenuation of the endothelial proinflammatory response, which was characterized by the inhibition of monocyte adhesion and adhesion molecule expression. This was due in part to enhanced nuclear factor-B (NF-B) transcriptional activity by acetylation at Lys672, which increased its binding on its target gene promoters. We determined that AMPK is an important inhibitor of p300 function, inhibiting p300 HAT activity by phosphorylation at Ser89. Specifically, loss of AMPK activity enhanced p300 HAT activity, which in turn increased NF-B acetylation and potently stimulated NF-Binduced transcription. Overall, our results demonstrate that hyperactivation of p300 HAT activity is responsible, at least in part, for increased NF-B transactivation potency and for the development of endothelial inflammation. These findings point to p300 phosphorylation at Ser89 by AMPK as critical for its therapeutic effect and highlight this process as a potential target for pharmaceutical intervention in proinflammatory states.
Materials and Methods
An expanded Methods section is available in the supplemental materials, available online at http://atvb.ahajournals.org.
Cell Culture
Human aortic ECs (HAECs) were cultured in M199 medium supplemented with FBS (20%), penicillin (100 U/mL), streptomycin (100 g/mL), heparin (90 g/mL), and EC growth supplement (20 g/mL). The cells were grown at 37°C in humidified 5% CO 2 and used for experiments between passages 3 and 5.
Results

AMPK Represses the Adhesive Response of Monocytes to Vascular Endothelial Cells
We first used a calcein-AM fluorescence-based adhesion assay to explore whether AMPK affects cell-cell adhesion between monocytes and ECs under proadhesive conditions. Exposure of HAECs to 5-aminoimidazole-4-carboxamide-1-␤-D-ribonucleotide (AICAR) for 24 hours suppressed human acute monocytic leukemia cell line-1 (THP-1) cell adhesion in a dose-dependent manner ( Figure 1A and 1B) . Coincubation with compound C, a potent AMPK inhibitor, completely reversed the effects of AICAR, suggesting AMPK dependent. AICAR also time-dependently inhibited THP-1 cell binding to HAECs, which plateaued after 24 hours of incubation ( Figure 1C ). Similar inhibitory effects were observed for unrelated AMPK agonists, such as metformin 24 and A-769662, 25 through the binding of fluorescence-labeled THP-1 cells to HAECs (Supplemental Figure IA) . To avoid the potential nonspecific effects of these drugs, we further transfected the ECs with plasmids encoding a constitutively active form of AMPK␣ (CA-AMPK␣) and a dominantnegative form of AMPK␣ (DN-AMPK␣). CA-AMPK␣ transfection caused a robust decrease in THP-1 adhesion. In contrast, overexpression of DN-AMPK␣ was unable to inhibit THP-1 adhesive response (Supplemental Figure IB) . The catalytic subunit of AMPK has 2 isoforms: ␣1 and ␣2. It was important to determine the relative contribution of each isoform. Selective depletion of AMPK␣1 by small interfering RNA (siRNA) dramatically abrogated the monocyte adherence, whereas AMPK␣2 depletion slightly abrogated it (Supplemental Figure IC) , showing that the AMPK␣1 subunit plays the dominant role. Taken together, these results suggest that AMPK functions as a negative regulator of the cytokineinduced adhesive responses in vascular ECs.
AMPK Decreases the Expression of VCAM-1 in Vascular ECs
VCAM-1 is a well-characterized mediator of monocyte adhesion to the endothelium, leading to the infiltration of monocytes into the subendothelial area and the development of atherosclerosis. 2 To investigate the underlying mechanism of AMPK-mediated inhibition of monocyte adhesion, we next evaluated the effect of AMPK on VCAM-1 expression in HAECs. AICAR treatment broadly and markedly repressed the ability of tumor necrosis factor-␣ (TNF-␣) to stimulate the expression of VCAM-1 mRNA ( Figure 1D ) and protein ( Figure 1E ) in HAECs. The effects of AICAR were almost completely abrogated by siRNA-mediated knockdown of AMPK, demonstrating that these antiinflammatory effects 
AMPK Suppresses p300-HAT Activity
Given these potent cellular selective antiinflammatory effects, we were interested in understanding the specific mechanisms whereby signals from AMPK inhibit inflammatory pathways. To further evaluate whether AMPK can suppress the acetylation of histones during endothelial inflammation, protein extracts from ECs treated with TNF-␣ alone or in the Figure IIIG) . We then analyzed the effect of AMPK on p300-HAT activity. AICAR treatment blocked TNF-␣-induced p300-HAT activity in a concentration-dependent manner ( Figure  2A ) and sustained this inhibition for all tested time points ( Figure 2B ). To confirm that the effect of AICAR was mediated by increased AMPK activity, CA-AMPK␣ and DN-AMPK␣ were separately overexpressed. As predicted, active AMPK␣ overexpression increased acetyl-CoA carboxylase phosphorylation, whereas the dominant-negative form suppressed it ( Figure 2C, top) . Under these conditions, CA-AMPK was revealed to markedly suppress TNF-␣-activated p300-HAT activity (Figure 2C, bottom) . To define the role of HDAC activity in AMPK-mediated histone hypoacetylation, the effect of AICAR on HDAC activity was determined. AICAR did not alter HDAC activity at each of the tested concentrations ( Figure 2D ). Collectively, these results argue that AMPK inhibits histone acetylation as a specific p300-HAT antagonist through inhibition of p300-HAT activity.
AMPK Blocks p300-Mediated Acetylation of NF-B p65 at Lysine 221
NF-B had been implicated in the transcriptional regulation of adhesion molecule genes. 26 To achieve maximum activation, NF-B must undergo a variety of posttranslational modifications, including acetylation. We found that the stimulation of HAECs with TNF-␣ strongly induced NF-B p65 acetylation at lysine 221 ( Figure 3A) . A previous report describing the regulation of NF-B activation by direct protein-protein interaction with p300 prompted us to investigate the functional significance of p300 in NF-B signaling. 27 Overexpression of p300 promoted TNF-␣-induced acetylation of NF-B p65, whereas DN-p300 expression prevented it ( Figure 3A and 3B ). Furthermore, incubation with TNF-␣ significantly enhanced NF-B p65 luciferase activity ( Figure  3C ) and VCAM-1 expression ( Figure 3D) in HAECs, and this effect was abolished by coincubation with Lys-CoA-TAT, a cell-permeable chemical inhibitor of p300 HAT. 16 This result was also confirmed by a siRNA specific to p300 ( Figure 3E and 3F). Because of the important role of lysines 218, 221. and 310 as major acetylation sites in p65, we next determined which individual lysine residue is essential for TNF-␣induced NF-B activation. As shown in Figure 3G , the mutation of lysine 221, but not 218 or 310, markedly decreased p65 acetylation in response to TNF-␣ compared with wild-type (WT) p65. Consistent with this result, TNF-␣ enhanced NF-B activation in cells transfected with WT p65, p65-Lys218Arg, and p65-Lys310Arg but not with the p65-Lys221Arg mutant ( Figure 3H ). Thus, it is evident that the lysine 221 residue is critical for mediating enhancement of p65 acetylation by TNF-␣ and the subsequent DNA-binding and transcriptional activity of NF-B.
Notably, AICAR treatment repressed the TNF-␣-induced increase in the acetylated form at lysine 221 of NF-B p65 ( Figure 4A ). Consistently, overexpression of CA-AMPK suppressed NF-B p65 Lys221 levels, whereas overexpression of DN-AMPK aggravated NF-B p65 acetylation in TNF-␣-treated ECs ( Figure 4B ). AICAR also diminished the TNF-␣-induced increase in the binding of NF-B p65 with p300 (Supplemental Figure IVA and IVB) . The amounts of total NF-B in the lysates after immunoprecipitation were similar among the 3 groups, indicating equal protein loading. For the reverse experiments, the same extracts were then immunoprecipitated with anti-p300 antibody, followed by immunoblotting with anti-NF-B antibody. AICAR still diminished the TNF-␣-mediated induction of p300 binding with NF-B (Supplemental Figure IVC and IVD) . Transfection with CA-AMPK abolished the TNF-␣-mediated induction of NF-B p65 luciferase activity, whereas DN-AMPK had no effect (Supplemental Figure IVE) . We also assessed NF-B DNA binding activity by using an ELISA-based assay. Notably, CA-AMPK, but not DN-AMPK, markedly suppressed the TNF-␣-mediated induction of NF-B p65 DNA binding activity (Supplemental Figure IVF) . In addition, the inhibitory effects of AMPK on NF-B transcriptional activity and DNA binding activity were reversed by infection with adenovirus-p300 (Supplemental Figure IVE and IVF). These findings demonstrate that AMPK abolishes TNF-␣-mediated NF-B activation by inhibiting p300induced acetylation of NF-B p65.
AMPK Prevents the Occupancy of VCAM-1 Promoter by p300 and NF-B p65
To further address the role of p300, we next examined whether p300 directly interacted with the VCAM-1 promoter in cultured ECs. Chromatin immunoprecipitation assays revealed that the recruitment of p300 and NF-B p65, as well as the acetylation levels of histones H3K9 and H4K8, at the VCAM-1 promoter were markedly increased after TNF-␣ stimulation ( Figure 4C-4F) . These results suggest that p300 and NF-B are associated with and co-occupy the VCAM-1 promoter on TNF-␣ stimulation. All these bindings were almost completely prevented by transfecting the ECs with CA-AMPK. In contrast, overexpression of DN-AMPK had no impact on the promoter occupancy. Furthermore, inhibition of p300 expression decreased the TNF-␣-stimulated association of NF-B p65 with the VCAM-1 promoter, demonstrating that p300 is necessary for the binding of NF-B to DNA ( Figure 4G ).
AMPK Induces the Ser89 Phosphorylation of p300
To understand the molecular mechanism underlying p300 inhibition by AMPK, we evaluated in the sites where p300 is phosphorylated by AMPK. We initially tested for phosphorylation at Ser89, which was shown to be a universal mechanism for regulating p300 transcriptional activity. Both AICAR and metformin stimulated p300 phosphorylation at the Ser89 site in HAECs ( Figure 5A ). We further cotransfected increasing amounts of an AMPK expression vector in HAECs, and this caused an increase in Ser89 phosphorylation of p300 ( Figure 5B ). Based on these effects, we next investigated whether phosphorylation at Ser89 of p300 by AMPK affected its physiological function. We transfected expression constructs containing a Gal4 DNA-binding do- main fused to either WT p300 (Gal4-WT-p300) or p300 containing a point mutation at Ser89 to alanine (Gal4-Ser89Ala-p300) into HAECs along with the AMPK constructs. Coexpression of CA-AMPK suppressed Gal4-WT-p300 activity by 3-fold compared with control, whereas CA-AMPK had no effect on Gal4-Ser89Ala-p300 activity ( Figure 5C ). Interestingly, Gal4-Ser89Ala-p300 was more active than Gal4-WT-p300, suggesting that phosphorylation of p300 by AMPK inhibits its transcriptional ability. This explanation was supported by the observation that compound C, an inhibitor of AMPK activity, markedly reduced amounts of Ser89 p300 phosphorylation in cells overexpressing CA-AMPK ( Figure 5D ), and as a result, its transcriptional activity was markedly increased ( Figure 5E ).
AMPK Induces p300 Phosphorylation via Atypical Protein Kinase C/ (aPKC/) Activation
Protein kinase C (PKC) was previously reported to mediate the phosphorylation of p300, 15 and analysis of the amino acid sequence of p300 led to the identification of Ser89 as a consensus recognition phosphorylation motif. 16 We further determined that the class of PKC is responsible for p300 phosphorylation at Ser89, and we treated vascular ECs with 2 PKC inhibitors. The nonisoform-selective PKC-specific inhibitor Ro31-8220 blocked AICAR-induced p300 phosphorylation; however, an inhibitor of classical and novel PKC isoforms, Go6976, had no effect ( Figure 6A ). These data suggest that AICAR mediates p300 phosphorylation through atypical PKCs (aPKCs). PKC and PKC/ constitute the aPKCs that are conserved across species and are ubiquitously expressed in most tissues. 28, 29 We then sought to identify the responsible PKC isoform using specific siRNA. RNA interference-mediated knockdown of aPKC/ in ECs blocked the induction of p300 phosphorylation by AMPK ( Figure 6B ). Furthermore, silencing of aPKC/ also markedly diminished AICAR-mediated reduction of monocyte adhesion (Supplemental Figure VA) and VCAM-1 expression (Supplemental Figure VB) . Transfection of an increasing amount of this aPKC/ expression vector caused the Ser89 phosphorylation of p300 ( Figure 6C ), supporting the notion that aPKC/ directly phosphorylates p300.
Phosphorylation plays an important role in activating PKC activity. For this reason, we examined the phosphorylation status of aPKC/. AICAR and AMPK overexpression stimulated phosphorylation of aPKC/ at Thr403 and Thr555 ( Figure 6D and 6E ), which are located in the activation loop of the kinase domain and have been shown to be critical for the kinase activity of aPKC/. Moreover, inhibition of PKC (Supplemental Figure VIA) or PKC (Supplemental Figure  VIB) by the TAT-conjugated peptide inhibitor did not interfere with the effects of AICAR on p300 phosphorylation. Thus, AMPK mediates p300 phosphorylation via aPKC/ activation.
Discussion
In this study, we show that AMPK functions as a p300-HAT inhibitor in proinflammatory ECs. By signaling through the phosphorylation of p300, AMPK activation through AICAR treatment and CA-AMPK overexpression mediates potent antiinflammatory effects to inhibit TNF-␣ inflammatory signaling pathways. The mechanism of AMPK-mediated antiinflammation involves the induction of p300 Ser89 phosphorylation and subsequent inactivation of p300 HAT activity, resulting in the attenuation of NF-B acetylation and its dependent monocyte adhesion to human ECs in response to TNF-␣ ( Figure 6F ). Because chronic tissue inflammation is an important mechanism that causes the generation of atherosclerotic lesions, the antiinflammatory actions of AMPK exert potent antiatherogenic effects.
AMPK is a crucial regulator of energy metabolic homeostasis and thus a major survival factor in a variety of metabolic stresses. 18 Recently, there have been several reports describing how the activation of AMPK can inhibit inflammatory response induced by different stimulating insults, whereas a decrease in AMPK activity is associated with increased inflammation. 30 -32 In this study, we demonstrated that pharmacological and genetic activation of AMPK decreases expression of adhesion molecules VCAM-1 in TNF-␣-activated ECs, thus preventing the adhesion of THP-1 cells to vascular ECs. The concentration of AMPK agonist AICAR used in this study seems high; however, this dosage of AICAR was commonly used and is comparable to the previous findings focused on the regulation of inflammation by AMPK. [33] [34] [35] [36] To exclude the off-target effects of AICAR, we used metformin and A-769662 as complementary methods of AMPK activation and found a consistent influence of these agents on monocyte adhesion. This contention is supported by our further observations that genetic activation of AMPK by CA-AMPK␣ mimics the protective effects of AICAR. All these data indicated that AMPK activation indeed suppressed endothelial inflammation. There are 2 isoforms of AMPK␣, each of which localizes to different subcellular compartments and downstream enzymes. Using RNA interference technology, we demonstrated the major contribution of the ␣1 isoform in AMPK-mediated regulation of TNF-␣-induced endothelial inflammation. This notion is inconsistent with a recent report showing that AICAR prevents postischemic inflammation by a mechanism involved with both isoforms. 36 This is discrepancy was mainly due to the predominant isoform expressed in ECs being the ␣1 catalytic subunit. 37, 38 NF-B is a key transcriptional factor involved in regulating the expression of proinflammatory mediators, including adhesion molecules, thereby playing a critical role in mediating inflammatory responses. 39 To achieve its biological functions, NF-B must undergo a variety of posttranslational modifications, including acetylation. 40, 41 Of particular interest, we provide direct evidence that acetylation of NF-B p65 by p300 constitutes a regulatory mechanism for TNF-␣-dependent VCAM-1 transcription and monocyte adhesion to ECs. First, suppression of p300-HAT activity results in impaired NF-B transcriptional activity, whereas upregulation of p300-HAT activity promotes NF-B activation, suggesting that p300-HAT plays a critical role in the activation of NF-B signaling. Actually, p300 was shown to recruit to the VCAM-1 promoter in a TNF-␣-dependent manner, promoting NF-B p65 binding, as well as histone H3K9 and H4K8 acetylation. Furthermore, the major acetylated site of NF-B p65 by p300 is the Lys221 residue located within its DNA-binding domain. Mutation of NF-B p65 Lys221 resulted in decreased DNA binding and transactivation activity, indicating that the acetylation of NF-B p65 is required for its capacity to interact with its target gene promoters. This observation correlates with previous reports showing that increasing acetylation within the DNA-binding domain of transcription factors, such as p53, 42 Nrf2, 43 or HNF4, 44 enhances their binding to the DNA, allowing an increase in their transcriptional activity. Although Lys221 was identified as the major acetylation site for NF-B p65, mutation of Lys218 appears to partially diminish the acetylation and transactivation of p65. Given that lysine 218 is located adjacent to lysine 221, it is possible that mutation of lysine 218 may interfere with the function of lysine 221 as a result of a possible conformational change. Taken together, our results demonstrate that p300 coactivates TNF-␣-mediated induction of proinflammatory gene expression by acetylating both histones and NF-B itself, which may contribute to increased association of NF-B p65 with the promoter.
Histone acetylation is regulated by p300-HAT and plays pivotal role in vascular disease. 45 The results of the present study indicate that inhibition of histone acetylation is a key mechanism for the antiinflammatory action of AMPK and that p300-HAT serves as its molecular target. By blocking p300-HAT activity, AMPK may inhibit the acetylation levels of both histone and NF-B itself, thus largely attenuating the increased occupancy of p300 and NF-B at the VCAM-1 promoter after treatment with TNF-␣. As a result, AMPK activation by AICAR treatment or CA-AMPK overexpression diminishes the amplification of the proinflammatory signaling cascades in the ECs. Together, these findings further indicate that AMPK protects from inflammation through the inhibition of p300 HAT activity. The p300associated HAT activity can be regulated by multiple mechanisms in addition to changes in p300 abundance, such as phosphorylation 46 and acetylation 47 of p300. We observed that AICAR treatment promoted the phosphorylation levels of p300 at Ser89 without affecting the overall cellular level of p300. Mutation of Ser89 to alanine abrogates AMPKmediated reduction of p300 transcriptional activity, confirming that the Ser89 is the major target of AMPK in regulation of HAT activity. aPKC/ represents a subgroup of the PKC family comprising the / and isoforms and is involved in several signal transduction pathways. 48 In the current study, we also provide a molecular link that aPKC/ mediates p300 phosphorylation by AMPK.
In conclusion, our present work demonstrates that AMPK prevents the development of the endothelial inflammatory response by blocking p300-HAT-dependent NF-B acetyla-tion. AMPK thus becomes an attractive therapeutic candidate for treating inflammatory diseases.
